BMY
Bristol-Myers Squibb
No price yet
Announcements
Nothing here yet
Daily updates
- Bristol Myers Squibb reported positive interim Phase 3 ACTION-1 results for RayzeBio’s RYZ101 in previously treated, SSTR-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The trial met its primary endpoint, demonstrating statistically significant and clinically meaningful progression-free survival benefits over standard care.Oct 12, 2026
- Bristol Myers Squibb reported positive topline Phase 3 ALOFT-IPF results: admilparant 60 mg twice daily significantly improved the change in forced vital capacity (FVC) at Week 52 versus placebo, meeting the primary endpoint, while the 120 mg dose slowed FVC decline without statistical significance.Oct 12, 2026
- Bristol Myers Squibb confirmed a limited number of liver-related safety events, including one death, in testing of pulmonary fibrosis candidate admilparant. The company said it remains unclear whether the drug caused the events, adding uncertainty around the emerging fibrosis drug class.Oct 4, 2026
- Bristol Myers Squibb amended its Phase 3 pulmonary fibrosis program for admilparant after reporting multiple liver injury cases, including one death. The trial remains blinded, so the company said the cause of the events has not yet been determined.Oct 1, 2026
- Bristol Myers Squibb's arlo-cel showed activity in heavily pretreated multiple myelomaSep 9, 2026
FDA designations
News
- Bristol Myers Squibb reports that the Phase 3 ALOFT-IPF trial of admilparant in adults with idiopathic pulmonary fibrosis met its primary endpointOct 12, 2026
- Bristol Myers Squibb reports positive topline results from the interim Phase 3 ACTION-1 analysis of RayzeBio’s radiopharmaceutical therapy RYZ101 in patients with GEP-NETsOct 12, 2026
- Bristol Myers reports liver injury events in its lung disease program ahead of a key clinical readoutOct 1, 2026
- Bristol Myers Squibb presented two-year Sotyktu data showing durable efficacy and consistent safety in adults with psoriatic arthritisSep 17, 2026
- Bristol-Myers Squibb's arlo-cel showed activity in post-BCMA multiple myeloma, potentially supporting future regulatory filingsSep 9, 2026